Correction: c-MET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors

Katia Corano Scheri; Erica Leonetti; Luigi Laino; Vincenzo Gigantino; Luisa Gesualdi; Paola Grammatico; Mariano Bizzarri; Renato Franco; J. Wolter Oosterhuis; Hans Stoop; Leendert H.J. Looijenga; Giulia Ricci; Angela Catizone

doi:10.18632/oncotarget.26374

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: c-MET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors

PDF | How to cite

Oncotarget. 2018; 9:36049-36049. https://doi.org/10.18632/oncotarget.26374

Metrics: PDF 1311 views | ?

Katia Corano Scheri¹, Erica Leonetti¹, Luigi Laino², Vincenzo Gigantino³, Luisa Gesualdi¹, Paola Grammatico², Mariano Bizzarri⁴, Renato Franco⁵, J. Wolter Oosterhuis⁶, Hans Stoop⁶, Leendert H.J. Looijenga⁶, Giulia Ricci^7,* and Angela Catizone^1,*

¹ Department of Anatomy, Histology, Forensic-Medicine and Orthopaedics, “Sapienza” University of Rome, Italy
² Department of Molecular Medicine, Laboratory of Medical Genetics, “Sapienza” University of Rome, San Camillo-Forlanini Hospital, Rome, Italy
³ Pathology Unit, Istituto Nazionale Tumori I.R.C.C.S. “Fondazione Pascale”, Naples, Italy
⁴ Department of Experimental Medicine, Systems Biology Group Lab, “Sapienza” University of Rome, Italy
⁵ Pathological Anatomy Unit, Department of Psychic and Physic health and preventive medicine, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy
⁶ Department of Pathology, Laboratory for Experimental Patho-Oncology, Erasmus MC University Medical Center, Cancer Institute, Rotterdam, The Netherlands
⁷ Department of Experimental Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy
^* These authors contributed equally to this work

Published: November 13, 2018

This article has been corrected: The correct author name is given below:

Mariano Bizzarri

Original article: Oncotarget. 2018; 9:31842-31860. DOI: https://doi.org/10.18632/oncotarget.25867.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26374

Publication Alerts

Corrections:

Correction: c-MET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors